Inopak Ltd – FDA 483, Aug 3, 2023
An FDA inspection of Inopak Ltd in Ringwood, NJ, a drug manufacturer, revealed significant deficiencies in its quality control unit's responsibilities and procedures. The firm failed to adequately evaluate formulations, review laboratory results, conduct stability studies, and review executed batch records for its OTC drug products. Additionally, Inopak Ltd lacked proper oversight for approving or rejecting contract-manufactured drug products and failed to perform critical testing like benzene content, impurities, and microbiological testing on several distributed products.
ID · 0d756d4b-4d77-43cc-b2d6-1311eee6b310
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.